Oral glutathione is poorly absorbed — most gets broken down before reaching cells. NAC is the amino acid precursor and consistently raises tissue glutathione levels through direct synthesis. For brain glutathione specifically, NAC has the stronger evidence. Liposomal glutathione is the exception where oral glutathione may work.
What glutathione does and why brain levels matter
Glutathione is the body's master intracellular antioxidant — a tripeptide of glutamate, cysteine, and glycine. It neutralizes reactive oxygen species, regenerates other antioxidants (vitamin C, vitamin E), and supports phase II liver detoxification.
In the brain, glutathione levels decline with age and are markedly reduced in Parkinson's, Alzheimer's, and other neurodegenerative conditions.[1] Raising or maintaining brain glutathione is a legitimate neuroprotective goal.
The problem: how you raise it matters enormously.
The absorption problem
| Compound | Oral bioavailability | Effect on tissue glutathione | Blood-brain barrier |
|---|---|---|---|
| Standard oral glutathione | Poor (broken down in gut) | Minimal in most trials | Doesn't cross well |
| Liposomal glutathione | Moderate | Emerging evidence (Sinha 2018) | Better than standard oral |
| NAC (N-acetyl cysteine) | Good (~10%) | Raises glutathione via synthesis | Crosses effectively |
| IV glutathione | 100% (bypasses gut) | Raises plasma levels acutely | Limited brain uptake |
| Whey protein (rich in cysteine) | Good | Modest tissue increase | Indirect |
Standard oral glutathione is broken down to its constituent amino acids in the digestive tract before it can be meaningfully absorbed intact. The Witschi 1992 trial demonstrated no meaningful rise in plasma glutathione after 3 g of oral glutathione in healthy adults.[2]
NAC works by providing cysteine — the rate-limiting amino acid in glutathione synthesis. Sekhar 2011 measured GSH synthesis rates in older adults given NAC + glycine for two weeks and found erythrocyte glutathione rose to youthful levels, along with improvements in insulin resistance and mitochondrial function markers.[3]
The NAC brain evidence
NAC has been tested in an unusual number of psychiatric and neurological conditions — Deepmala 2015 systematic review found trial data spanning schizophrenia, bipolar disorder, OCD, autism, trichotillomania, PTSD, and cannabis use disorder.[4]
Berk 2008 tested 1 g NAC twice daily as add-on therapy in bipolar disorder patients over 24 weeks. Significant improvements in Montgomery-Åsberg Depression Rating Scale scores vs placebo.[5]
Berk 2008 (separate paper) tested 1 g NAC twice daily as add-on in schizophrenia over 24 weeks. Significant improvements in Positive and Negative Syndrome Scale scores.[6]
The mechanism spans more than glutathione — NAC also modulates glutamate transmission, which likely contributes to the psychiatric signals.
The liposomal glutathione exception
Liposomal glutathione — glutathione encapsulated in phospholipid vesicles — appears to bypass the digestion problem. Sinha 2018 tested liposomal glutathione in 54 adults over 4 weeks at 500-1000 mg/day and measured increases in body glutathione stores (RBC, plasma, lymphocyte).[7]
This is a small trial with a specific proprietary product. The data is emerging, not definitive. But if you want glutathione directly rather than via NAC-mediated synthesis, liposomal is the only oral form with any real support.
STRONG: NAC for raising tissue glutathione via synthesis (multiple RCTs).EMERGING: Liposomal glutathione for direct GSH supplementation (small trials).WEAK: Standard oral glutathione for tissue glutathione (poor absorption).Where each fits
- NAC: the default for raising brain and body glutathione at low cost. Also unique benefits in psychiatric conditions.
- Liposomal glutathione: reasonable if you have a specific reason to raise glutathione directly rather than via synthesis (some acute detox protocols).
- Standard oral glutathione: mostly a waste of money — the science on absorption is unambiguous.
- IV glutathione: raises plasma glutathione acutely but doesn't reach brain tissue well. Used clinically for specific indications (paracetamol overdose, some Parkinson's protocols).
Dosing and cautions
Standard NAC dose in most trials is 600-1200 mg twice daily. Some psychiatric trials go higher (up to 2400 mg twice daily). Take on an empty stomach or with food — either works.
NAC has an unpleasant sulfurous taste and smell. Enteric-coated capsules are more tolerable than raw powder.
Interactions: NAC can potentiate nitrates (used for angina) and may reduce the therapeutic effect of activated charcoal. If you're on prescription cardiovascular medications, check with your doctor.
What to actually buy
Jarrow Formulas NAC Sustain
Sustained-release NAC at 600 mg, split delivery reduces the sulfur burp. Third-party tested.
Check Amazon price →Quicksilver Scientific Liposomal Glutathione
One of the more validated liposomal glutathione products with published pharmacokinetic data on the specific liposomal delivery system.
Check Amazon price →NOW NAC 600mg
Standard NAC at trial-verified doses. Third-party tested by NOW. Solid budget pick for a daily antioxidant/glutathione protocol.
Check Amazon price →Citations
- Mischley LK, et al. Central nervous system uptake of intranasal glutathione in Parkinson's disease. NPJ Parkinsons Dis. 2016;2:16002.
- Witschi A, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669.
- Sekhar RV, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr. 2011;94(3):847-853.
- Deepmala, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294-321.
- Berk M, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361-368.
- Sinha R, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018;72(1):105-111.